Immunotherapy Advances in Non-Small Cell Lung Cancer: A 2026 Research Update

Non-small cell lung cancer (NSCLC) is a group of lung cancers accounting for roughly 80–85% of all lung cancer diagnoses, most commonly adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Over the past decade, the treatment of NSCLC has been transformed by immune checkpoint inhibitors — drugs that release the brakes on the immune system so it can attack cancer cells. This article summarizes what the published research shows about these therapies, who benefits, and the limitations clinicians are still working to understand.

Background: why immunotherapy changed NSCLC

Before 2015, advanced NSCLC had few effective treatment options beyond platinum-based chemotherapy, and median overall survival was typically measured in months rather than years [7]. Immune checkpoint inhibitors target proteins like PD-1 (on T cells) or PD-L1 (often on tumor cells) that normally prevent the immune system from attacking the body's own tissues. Blocking these checkpoints allows T cells to recognize and destroy tumor cells in a subset of patients [9].

The first landmark trial, KEYNOTE-024, compared pembrolizumab — a PD-1 inhibitor — to standard chemotherapy as first-line treatment in patients whose tumors expressed PD-L1 on at least 50% of cells. Pembrolizumab significantly improved progression-free and overall survival [1]. That result shifted guidelines almost immediately.

The current research landscape

Several checkpoint inhibitors are now established in NSCLC care, each with supporting evidence from large randomized trials:

• Pembrolizumab monotherapy — first line for metastatic NSCLC with PD-L1 ≥ 50% and no EGFR/ALK alterations [1].
• Pembrolizumab + chemotherapy — the KEYNOTE-189 trial showed improved survival versus chemotherapy alone in metastatic nonsquamous NSCLC regardless of PD-L1 level [2].
• Nivolumab — demonstrated survival benefit over docetaxel in previously treated nonsquamous NSCLC (CheckMate 057) [3].
• Nivolumab + ipilimumab — dual checkpoint blockade was tested in CheckMate 227 in first-line advanced NSCLC [4].
• Atezolizumab — a PD-L1 inhibitor with first-line evidence in PD-L1–selected patients (IMpower110) [8].
• Durvalumab after chemoradiotherapy — the PACIFIC trial established durvalumab consolidation as standard of care for unresectable stage III NSCLC after chemoradiation [6].
• Neoadjuvant nivolumab + chemotherapy — the CheckMate 816 trial showed benefit of giving nivolumab plus chemotherapy before surgery in resectable NSCLC [5].

Key findings: what the trials tell us

A few themes emerge across the published literature:

• PD-L1 expression matters, but imperfectly. High PD-L1 expression (≥ 50%) predicts stronger benefit from checkpoint inhibitor monotherapy, but some patients with low or no PD-L1 expression still respond, and some with high PD-L1 do not [1][2].
• Adding chemotherapy broadens who benefits. Combining pembrolizumab with chemotherapy allowed first-line immunotherapy to move beyond the PD-L1–high subgroup [2].
• Earlier-stage disease is increasingly treated.Checkpoint inhibitors were first approved in metastatic disease, but trials like PACIFIC and CheckMate 816 show benefit in stage III and resectable disease [5][6].
• Responses can be durable. Long-term follow-up from multiple trials shows a subset of patients remain alive and progression-free years after treatment — something rarely seen with chemotherapy alone [7].

Clinical implications

NSCLC treatment is now biomarker-driven. Before choosing first-line therapy, oncologists typically test for:

• PD-L1 expression — to determine eligibility for single-agent checkpoint inhibition
• Driver mutations — such as EGFR, ALK, ROS1, BRAF, MET, RET, KRAS G12C, and NTRK, which may respond better to targeted therapies than to immunotherapy [7][11]
• Tumor mutational burden — explored as a predictive biomarker in selected trials

NCCN and national guidelines now recommend tailoring first-line treatment based on these markers [11]. This is why molecular testing on a biopsy sample is essential before starting therapy.

Side effects clinicians watch for

Immune checkpoint inhibitors can cause immune-related adverse events (irAEs) — the immune system attacking normal tissues. Published reviews describe a spectrum that includes thyroid dysfunction, pneumonitis, colitis, hepatitis, and skin reactions, among others [9]. Most are mild or moderate and manageable with corticosteroids, but a minority are serious and occasionally life-threatening. Recognizing irAEs early is critical; clinicians typically monitor bloodwork and symptoms at each visit.

What remains unclear

• Who benefits most from combination immunotherapy versus monotherapy remains an active research question.
• Optimal duration of treatment — some trials used fixed 2-year regimens while others continued until progression.
• How to re-challenge patients whose cancer progresses after initial immunotherapy response.
• Whether specific irAE patterns predict better anti-tumor response.
• Integration with emerging modalities such as antibody–drug conjugates.

Frequently asked questions

Is immunotherapy always the best option for lung cancer? No. Tumors driven by certain mutations (EGFR, ALK, ROS1) typically respond best to targeted therapies as first-line treatment, not to immunotherapy. Biomarker testing before treatment is important [7][11].

Can immunotherapy cure lung cancer? Trial data show some patients experience durable long-term control, but the word "cure" is used cautiously in metastatic disease. Long-term follow-up data from multiple trials describe a subset of patients with remarkable durability [7]; individual prognosis depends on many factors.

Are there costs or access issues? Checkpoint inhibitors are expensive and availability varies significantly by country and insurance coverage. Discuss with your oncology team whether clinical trials or patient-assistance programs might apply to your situation.

What if my tumor does not express PD-L1? You may still benefit from a combination approach, such as immunotherapy plus chemotherapy, which the KEYNOTE-189 trial showed improves outcomes regardless of PD-L1 level [2]. Your oncologist will review your own situation.

When to talk to a doctor

If you or a loved one has recently been diagnosed with non-small cell lung cancer, it is worth discussing with a doctor:

• Whether your biopsy has been tested for PD-L1 expression and driver mutations
• What stage your cancer is and what options exist at that stage
• Whether a second opinion at a comprehensive cancer center is appropriate
• Whether clinical trials in your area could add to your options
• Symptoms of immune-related side effects if you are already on treatment

Heliodoc provides access to verified general practitioners who can help you interpret a diagnosis, prepare for specialist appointments, and organize records before a second opinion. For specialist oncology care, your doctor will coordinate referral to an oncology team. Learn more about finding a doctor on Heliodoc.